MorphoSys (Novartis)
German antibody company that acquired Constellation's BET inhibitor pelabresib and was itself bought by Novartis in 2024.
MorphoSys developed tafasitamab (Monjuvi, CD19, DLBCL) and acquired Constellation Pharmaceuticals (2021) for pelabresib, a BET inhibitor studied in myelofibrosis (MANIFEST-2). Novartis completed its acquisition of MorphoSys in 2024; tafasitamab rights had moved to Incyte.
Pages like this
not linked directly; found by shared links- PersonChristopher R. Flowers
Shares CD19, Diffuse large B-cell lymphoma.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares CD19, Diffuse large B-cell lymphoma.
- CompanyNkarta
Shares CD19, Diffuse large B-cell lymphoma.
- PersonRonald Levy
Shares Monoclonal antibodies, Diffuse large B-cell lymphoma.
- ProductTafasitamab
Shares CD19, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Monoclonal antibodies, Diffuse large B-cell lymphoma.
- InstitutionNational University Hospital / National University Cancer Institute, Singapore
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Diffuse large B-cell lymphoma.
- Key paperJULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma
Shares Novartis, CD19, Diffuse large B-cell lymphoma.